The spike mutations for the P.1 variant included L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I and V1176F. is over 230-fold more potent than its parental IgG-14 in neutralizing SARS-CoV-2. IgM-14 potently neutralizes the resistant computer virus raised by its corresponding IgG-14, three variants of concernB.1.1.7 (Alpha, which first emerged in the UK), P.1 (Gamma, which first emerged in Brazil) and B.1.351 (Beta, which first emerged in South Africa)and 21 other receptor-binding domain name mutants, many of which are resistant to the IgG antibodies that have been authorized for emergency use. Although engineering IgG into IgM enhances antibody potency Loureirin B in general, selection of an optimal epitope is critical for identifying the most effective IgM that Loureirin B can overcome resistance. In mice, a single intranasal dose of IgM-14 at 0.044 mg per kg body weight confers prophylactic efficacy and a single dose at 0.4 mg per kg confers therapeutic efficacy against SARS-CoV-2. IgM-14, but not IgG-14, also confers potent therapeutic protection against the P.1 and B.1.351 variants. IgM-14 exhibits desirable pharmacokinetics and safety profiles when administered intranasally in rodents. Our results show that intranasal administration of an designed IgM can improve efficacy, reduce resistance and simplify the prophylactic and therapeutic treatment of COVID-19. The respiratory tract is the major target for SARS-CoV-2 contamination5. High viral load in the respiratory tract correlates with severe disease in patients with COVID-196. So far, almost all neutralizing monoclonal antibodies (monoclonal antibodies) that have been tested in clinical trials are the IgG1 isotype and are administered through intravenous infusion. Circulating IgG antibodies lack efficient access to mucosal compartments7. After intravenous infusion, antibody levels in the lung are around 200C500 times lower than those in the serum8. Potent neutralizing IgG1 monoclonal antibodies need to be administered at high doses (up to 8 g); even so, the antiviral effect is small in the respiratory tract in patients treated with drug compared to those treated with placebo9. Emerging Rabbit polyclonal to DYKDDDDK Tag SARS-CoV-2 variants of concern (VOCs) are resistant to many potent neutralizing IgG1 monoclonal antibodies, including those that are in clinical trials and that have been authorized for emergency use2-4. Therefore, the development of new antibody therapies that can overcome these challenges is urgently needed. IgM and IgA are mucosal antibodies that constitute the first line of defence against mucosal pathogens. Typically, IgM assembles into pentamers and IgA1 into dimers in the presence of the joining chain (J-chain), which facilitates efficient mucosal transcytosis of antibodies10,11. IgM and IgA1 can also be nebulized and reach airway tissues after inhalation12. Owing to avidity effects, multivalent antibodies can exhibit enhanced neutralization of SARS-CoV-213 and reduce the evasion of antibodies by the computer virus14. An IgM pentamer is usually naturally decavalent owing to the repetitive antigen-binding variable fragments (Fvs)11. These unique features make the intranasal delivery of IgM neutralizing monoclonal antibodies appealing for the prevention and treatment of COVID-19. Engineering of neutralizing IgM and IgA1 To develop human IgM and IgA1 neutralizing monoclonal Loureirin B antibodies, we performed antibody engineering based on the CR3022 monoclonal antibody15 and five IgG1 monoclonal antibodies (CoV2-06, CoV2-09, CoV2-12, CoV2-14 and CoV2-16) that were previously isolated from a phage-displayed antibody library1. These six monoclonal antibodies recognize different epitopes around the receptor-binding domain name (RBD) (Fig. 1a, Extended Data Fig. 1a, ?,b).b). The Fv of IgG1 was designed into human IgM or IgA1 scaffolds for co-expression with the J-chain. The designed IgM is usually a pentamer and IgA1 is usually a dimer (Fig. 1b). After production, the monoclonal antibodies of different isotypes assembled correctly and exhibited a purity of greater than 95% (Fig. 1c, ?,d).d). IgM and IgA1 bound to the RBD more strongly than did IgG1 (Fig. 1e, Extended Data Fig. 1c). The higher binding activities, as evidenced by smaller values of the half-maximal effective concentration (EC50), were consistent with the.